Long-term Incentive Plans (Tables)
|
12 Months Ended |
Jan. 31, 2026 |
|---|
| Long-term Incentive Plans |
|
| Schedule of continuity of the company's performance stock units (PSUs) |
| | Number of PSUs | | | | | | Outstanding, January 31, 2024 and 2023 | | | 25,000 | | Granted (Note 14) | | | 6,000,000 | | | | | | | Outstanding, January 31, 2025 | | | 6,025,000 | | Forfeited (Note 14) | | | 800,000 | | | | | | | Outstanding, January 31, 2026 | | | 5,225,000 | |
|
| Schedule of performance stock units Outstanding |
Number of PSUs | | | Vesting Provisions | | | | | | 25,000 | | | Vested on March 31, 2021 | | 5,200,000 | | | Volume weighted average common share price for five consecutive dates: $0.30 – 33.33%; $0.50 – 33.33%; $1.00 – 33.34% | | 5,225,000 | | | |
|
| Schedule of assumptions used for fair value of share-based payment expense of PSU |
| | | January 31, 2026 | | | | January 31, 2025 | | Date of grant or valuation | | | January 31, 2026 | | | | December 16, 2024 | | Risk free interest rate | | | 2.56% | | | | 2.96% | | Volatilities | | | 119% | | | | 114% | | Fair value of common shares on grant date | | | $0.05 | | | | $0.11 | | Expected dividends | | | Nil% | | | | Nil% | | Expected life | | | 1.87 years | | | | Three (3) years | | Fair value of PSUs on grant date | | | $0.05 | | | | $0.08 | |
|
| Schedule of continuity of the company's share purchase options |
| | Number of Options | | | Weighted Average Exercise Price | | | Weighted Average Remaining Contractual Life (years) | | Outstanding, January 31, 2023 | | | 6,270,000 | | | | 0.38 | | | | 1.93 | | Granted (Note 14) | | | 6,045,000 | | | | 0.07 | | | | 3.00 | | Forfeited/expired (Note 14) | | | (2,100,000 | ) | | | (0.60 | ) | | | – | | Outstanding, January 31, 2024 | | | 10,215,000 | | | | 0.15 | | | | 1.94 | | Granted (Note 14) | | | 2,150,000 | | | | 0.14 | | | | 3.00 | | Expired | | | (20,000 | ) | | | (0.16 | ) | | | – | | Outstanding, January 31, 2025 | | | 12,345,000 | | | | 0.15 | | | | 1.24 | | Granted (Note 14) | | | 900,000 | | | | 0.09 | | | | 4.33 | | Forfeited/expired (Note 14) | | | (4,150,000 | ) | | | (0.27 | ) | | | – | | Outstanding, January 31, 2026 | | | 9,095,000 | | | | 0.09 | | | | 0.94 | |
|
| Schedule of additional information about share purchase options |
Options Outstanding | | | Options Exercisable | | | Exercise Price $ | | | Expiry Date | | Vesting Terms | | | | | | | | | | | | | | | | 5,595,000 | | | | 5,595,000 | | | | 0.075 | | | May 1, 2026 | | 25% every six months | | | 200,000 | | | | 200,000 | | | | 0.07 | | | June 19, 2026 | | 25% every six months | | | 250,000 | | | | 250,000 | | | | 0.07 | | | July 31, 2026 | | 40% on grant date; 20% every two months thereafter | | | 200,000 | | | | 100,000 | | | | 0.08 | | | April 7, 2027 | | 25% every six months | | | 2,150,000 | | | | 2,150,000 | | | | 0.14 | | | October 7, 2027 | | 100% on grant date | | | 700,000 | | | | 350,000 | | | | 0.09 | | | July 1, 2030 | | 25% every six months | | | 9,095,000 | | | | 8,645,000 | | | | | | | | | |
|
| Schedule of assumptions used for fair value of share purchase options |
| | January 31, 2026 | | January 31, 2025 | | | January 31, 2024 | | Dates of grant or valuation | | April 8, 2025 to January 31, 2026 | | October 8, 2024 | | | May 2, 2023 to January 31, 2024 | | Risk free interest rates | | 2.45% to 2.91% | | 3.03% | | | 3.48% to 4.63% | | Volatilities | | 110% to 129% | | 112% | | | 109% to 144% | | Fair values of common shares on grant or valuation dates | | $0.05 to $0.09 | | $0.145 | | | $0.065 to $0.08 | | Expected dividends | | Nil% | | Nil% | | | Nil% | | Expected lives | | Two (2) and five (5) years | | Three (3) years | | | 1.95 years to three (3) years | | Exercise prices | | $0.08 and $0.09 | | $0.14 | | | $0.07 to $0.16 | | Fair values of options on grant or valuation dates | | $0.019 to $0.077 | | $0.10 | | | $0.04 to $0.17 | |
|
| Summary of the continuity of MedMelior's share purchase options |
| | Number of Options | | | Weighted Average Exercise Price | | | Weighted Average Remaining Contractual Life (years) | | | | | | | | | | | | Outstanding, January 31, 2024 and 2023 | | | 1,100,000 | | | | 0.10 | | | 0.91 / 1.91 / 2.91 | | Granted (Note 14) | | | 2,200,000 | | | | 0.10 | | | | 1.50 | | Expired (Note 14) | | | (1,100,000 | ) | | | (0.10 | ) | | | – | | | | | | | | | | | | | | | Outstanding, January 31, 2025 | | | 2,200,000 | | | | 0.10 | | | | 0.73 | | Expired (Note 14) | | | (2,200,000 | ) | | | (0.10 | ) | | | – | | | | | | | | | | | | | | | Outstanding, January 31, 2026 | | | – | | | | – | | | | – | |
|
| Schedule of assumptions used for fair value of share purchase options of MedMelior |
| | | January 31, 2025 | | Date of grant | | | April 25, 2024 | | Risk free interest rate | | | 4.44% | | Volatility | | | 99% | | Fair value of common shares on grant date | | | $0.86 | | Expected dividends | | | Nil% | | Expected life | | | 1.5 years | | Exercise price | | | $0.10 | | Fair value of options on grant date | | | $0.77 | |
|